008930.KO Hanmi Science
- Market cap
- KRW 3.56T
- P/E
- 22.0x
- P/B
- 3.13x
- ROE
- 16.3%
- Dividend yield
- 0.38%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 008930.KO undervalued?
Graham number008930.KO trades 74.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hanmi Science fundamental analysis
No fundamental analysis for Hanmi Science yet.
Hanmi Science stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hanmi Science
Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult's bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition, it offers automated drug management systems. The company sells its products th…
Full company profileHanmi Science financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hanmi Science annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 665B | 652B | 708B | 817B | 857B | 950B | 1.05T | 1.25T | 1.28T | 1.36T | 1.49T |
| Gross Profit | 665B | 652B | 92.4B | 108B | 121B | 133B | 162B | 265B | 273B | 316B | 942B |
| Operating Income | 15.1B | 14.0B | 11.0B | 16.1B | 25.2B | 28.8B | 28.1B | 57.0B | 38.0B | 57.0B | 110B |
| EBITDA | - | 39.3B | 24.5B | 43.5B | 37.9B | 56.2B | 82.3B | 149B | 84.2B | 153B | 222B |
| Net Income | 7.94B | 30.1B | 18.0B | 30.7B | 22.6B | 42.9B | 69.2B | 115B | 59.4B | 118B | 173B |
| EPS | - | 465 | 279 | 475 | 349 | 638 | 1,038 | 1,693 | 878 | 1,748 | 2,551 |
| Balance Sheet | |||||||||||
| Total Assets | 969B | 939B | 917B | 911B | 923B | 950B | 1.11T | 1.23T | 1.35T | 1.49T | 1.53T |
| Total Liabilities | 322B | 274B | 263B | 265B | 264B | 260B | 385B | 439B | 510B | 530B | 472B |
| Shareholders' Equity | 645B | 665B | 653B | 646B | 659B | 690B | 725B | 788B | 841B | 962B | 1.06T |
| Cash & Short-term Investments | 103B | 38.4B | 26.9B | 16.7B | 14.8B | 16.6B | 21.4B | 27.6B | 85.2B | 127B | 98.3B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 76.5B | -33.7B | 2.70B | 13.0B | 13.8B | 13.7B | 9.45B | 35.2B | 83.0B | 47.7B | 36.8B |
| Capital Expenditure | 6.03B | 2.21B | 770M | 1.25B | 958M | 1.82B | 8.34B | 8.68B | 11.6B | 20.9B | 14.0B |
| Free Cash Flow | - | -37.8B | 1.52B | 11.1B | 11.9B | 11.5B | 1.11B | 26.5B | 71.3B | 26.7B | 22.8B |
| Ratios | |||||||||||
| ROE | 1.2% | 4.5% | 2.8% | 4.8% | 3.4% | 6.2% | 9.5% | 14.6% | 7.1% | 12.3% | 16.3% |
| ROA | 0.8% | 3.2% | 2.0% | 3.4% | 2.4% | 4.5% | 6.2% | 9.4% | 4.4% | 7.9% | 11.3% |
| Net Profit Margin | 1.2% | 4.6% | 2.5% | 3.8% | 2.6% | 4.5% | 6.6% | 9.2% | 4.6% | 8.7% | 11.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Hanmi Science dividends
- Dividend yield
- 0.38%
- Forward dividend
- 300.00 KRW
- Payout ratio
- 11.4%
- Ex-dividend date
- Mar 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 13.5B | 200 | 11.4% |
| 2024 | KRW 20.3B | 300 | 34.2% |
| 2023 | KRW 13.3B | 196 | 11.6% |
| 2022 | KRW 13.2B | 198 | 19.1% |
| 2021 | KRW 12.9B | 192 | 30.1% |
| 2020 | KRW 12.7B | 196 | 56.1% |
| 2019 | KRW 12.4B | 192 | 40.5% |
| 2018 | KRW 12.2B | 188 | 67.7% |
| 2017 | KRW 12.2B | 188 | 40.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.02:1 on Dec 28, 2022.
Who owns Hanmi Science
- Insiders 71.97%
- Institutions 9.08%
- Public & others 18.96%
- Shares outstanding 67.8M
- Free float 26.6M
Hanmi Science company profile
- Company name
- Hanmi Science
- Ticker
- 008930.KO
- ISIN
- KR7008930000
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 492
- Fiscal year end
- December
- Address
- 14 Wiryeseong-daero, Seoul, South Korea, 05545
- Phone
- 82 2 410 9114
- Website
- hanmiscience.co.kr
About Hanmi Science
Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult's bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition, it offers automated drug management systems. The company sells its products through online and offline pharmacies. The company was formerly known as Hanmi Holdings Co., Ltd. and changed its name to Hanmi Science Co., Ltd. in March 2012. Hanmi Science Co., Ltd. was founded in 1973 and is headquartered in Seoul, South Korea.
Hanmi Science management
4- Mr. Jong-Hoon LimChief Executive Officer · born 1961
- Ms. Ju-Hyun LimPresident & Inside Director · born 1974
- Mr. Chan Seob KimCFO & Senior MD · born 1965
- Moon-hee LeeGeneral Manager of clinical team leader